References
- Monticelli J, Di Bella S, Giacobbe DR, et al. Trends in the incidence and antibiotic resistance of enterococcal bloodstream isolates: a 7-year retrospective multicenter epidemiological study in Italy. Microb Drug Resist. 2021;27(4):529–535. doi: 10.1089/mdr.2020.0147.
- Mercuro NJ, Davis SL, Zervos MJ, et al. Combatting resistant enterococcal infections: a pharmacotherapy review. Expert Opin Pharmacother. 2018;19(9):979–992. doi: 10.1080/14656566.2018.1479397.
- Lagatolla C, Mehat JW, La Ragione RM, et al. In vitro and in vivo studies of oritavancin and fosfomycin synergism against vancomycin-resistant. Antibiotics. 2022;11(10):1334. doi: 10.3390/antibiotics11101334.
- Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091–1098. doi: 10.1093/cid/ciy1054.
- Bahrs C, Rieg S, Hennigs A, et al. Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study. Clin Microbiol Infect. 2023;29(2):200–207. doi: 10.1016/j.cmi.2022.08.023.
- Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2018;62(1):e01453-17. doi: 10.1128/AAC.01453-17.
- Britt NS, Potter EM, Patel N, et al. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017;64(5):605–613.
- Johnson JA, Feeney ER, Kubiak DW, et al. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis. 2015;2(4):ofv156.
- Carvalhaes CG, Sader HS, Streit JM, et al. Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010-2019). Antimicrob Agents Chemother. 2022;66(2):e0166721. doi: 10.1128/AAC.01667-21.